Choice of anticoagulant therapy in an elderly patient with atrial fibrillation and high risk of hemorrhage

1. Kim DH, Pawar A, Gagne JJ, Bessette LG, Lee H, Glynn RJ. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: A cohort study. Ann Intern Med. 2021;174(9):1214–23.

PMID: 34280330. PMCID: PMC8453126. https://doi.org/10.7326/M20-7141

2. Shah SJ, Fang MC, Jeon SY, Gregorich SE, Covinsky KE. Geriatric syndromes and atrial fibrillation: Prevalence and association with anticoagulant use in a national cohort of older Americans. J Am Geriatr Soc. 2021;69(2):349–56.

PMID: 32989731. PMCID: PMC8174581. https://doi.org/10.1111/jgs.16822

3. Proietti M, Romiti GF, Raparelli V, Diemberger I, Boriani G, Dalla Vecchia LA et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. Ageing Res Rev. 2022;79:101652.

PMID: 35659945. https://doi.org/10.1016/j.arr.2022.101652

4. Sison SDM, Lin KJ, Najafzadeh M, Ko D, Patorno E, Bessette LG et al. Common non-cardiovascular multimorbidity groupings and clinical outcomes in older adults with major cardiovascular disease. J Am Geriatr Soc. 2023;71(10):3179–88.

PMID: 37354026. PMCID: PMC10592495. https://doi.org/10.1111/jgs.18479

5. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circ Cardiovasc Qual Outcomes. 2012;5(1):85–93.

PMID: 22235070. PMCID: PMC3332107. https://doi.org/10.1161/circoutcomes.111.962688

6. Siontis KC, Gersh BJ, Weston SA, Jiang R, Roger VL, Noseworthy PA et al. Associations of atrial fibrillation after noncardiac surgery with stroke, subsequent arrhythmia, and death: A cohort study. Ann Intern Med. 2022;175(8):1065–72.

PMID: 35878404. PMCID: PMC9483925. https://doi.org/10.7326/M22-0434

7. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98(10):946–52.

PMID: 9737513. https://doi.org/10.1161/01.cir.98.10.946

8. Diaz-Arocutipa C, Carvallo-Castañeda D, Chumbiauca M, Mamas MA, Hernandez AV. Impact of frailty on clinical outcomes in patients with atrial fibrillation who underwent cardiac ablation using a nationwide database. Am J Cardiol. 2023;203:98–104.

PMID: 37487408. https://doi.org/10.1016/j.amjcard.2023.07.020

9. Wang A, Ferro EG, Xu J, Song Y, Sun T, Strom JB et al. Comparative performance of distinct frailty measures among patients undergoing percutaneous left atrial appendage closure. Pacing Clin Electrophysiol. 2023;46(3):242–50.

PMID: 36530151. PMCID: PMC9998344. https://doi.org/10.1111/pace.14649

10. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–414.

PMID: 39210723. https://doi.org/10.1093/eurheartj/ehae176

11. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М.В. с соавт. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594.

EDN: FUZAAD. https://doi.org/10.15829/1560-4071-2021-4594

12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

PMID: 19717844. https://doi.org/10.1056/NEJMoa0905561

13. Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103(13):1015–23.

PMID: 28213368. https://doi.org/10.1136/heartjnl-2016-310358

14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

PMID: 21830957. https://doi.org/10.1056/NEJMoa1009638

15. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR et al.; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138–46.

PMID: 24895454. https://doi.org/10.1161/circulationaha.113.005008

16. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

PMID: 21870978. https://doi.org/10.1056/nejmoa1107039

17. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864–72.

PMID: 24561548. PMCID: PMC4104493. https://doi.org/10.1093/eurheartj/ehu046.

18. Лукьянов М.М., Бойцов С.А., Якушин С.С., Марцевич С.Ю., Воробьев А.Н., Загребельный А.В. с соавт. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2014;10(4):366–377. EDN: SNKFPX.

19. Hanon O, Vidal JS, Pisica-Donose G, Orvoën G, David JP, Chaussade E et al.; SAFIR study group. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107(17):1376–82.

PMID: 33262185. https://doi.org/10.1136/heartjnl-2020-317923

20. Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study; (SOFIA). ClinicalTrials.gov ID: NCT04586972. URL: https://clinicaltrials.gov/study/NCT04586972 (date of access – 10.04.2025).

21. Gadde S, Kalluru R, Cherukuri SP et al. Atrial fibrillation in chronic kidney disease: An overview. Cureus. 2022;14(8):e27753.

PMID: 36106212. PMCID: PMC9445413. https://doi.org/10.7759/cureus.27753

22. Ding WY, Gupta D, Wong CF et al. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res. 2021;117(4):1046–59.

PMID: 32871005. https://doi.org/10.1093/cvr/cvaa258

23. Airy M, Schold JD, Jolly SE et al. Cause-specific mortality in patients with chronic kidney disease and atrial fibrillation. Am J Nephrol. 2018;48(1):36–45.

PMID: 30048961. PMCID: PMC6107349. https://doi.org/10.1159/000491023

24. Lobos-Bejarano JM, Castellanos Rodríguez A, Barrios V et al. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. Int J Clin Pract. 2017;71(9):e12974.

PMID: 28722795. https://doi.org/10.1111/ijcp.12974

25. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.

PMID: 24315724. https://doi.org/10.1016/S0140-6736(13)62343-0

26. Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–94.

PMID: 21873708. https://doi.org/10.1093/eurheartj/ehr342

27. Di Lullo L, Tripepi G, Ronco C et al. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: Real world data. J Nephrol. 2018;31(5):751–56.

PMID: 29882198. https://doi.org/10.1007/s40620-018-0501-7

28. Weir MR, Haskell L, Berger JS et al. Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function. Clin Nephrol. 2018;89(5):314–29.

PMID: 29231162. https://doi.org/10.5414/cn109281

29. Rivera-Caravaca JM, Anguita Sanchez M, Sanmartín Fernández M et al. Adverse clinical outcomes and associated predictors in rivaroxaban-treated atrial fibrillation patients with renal impairment. Am J Cardiol. 2023;203:122–27.

PMID: 37487406. https://doi.org/10.1016/j.amjcard.2023.06.105

30. Чашкина М.И., Андреев Д.А., Козловская Н.Л., Салпагарова З.К., Суворов А.Ю., Сучкова С.А. с соавт. Показатели безопасности ривароксабана по сравнению с варфарином у пациентов с фибрилляцией предсердий и хронической болезнью почек поздних стадий. Кардиология. 2020;60(11):94–100.

EDN: XXRRNI. https://doi.org/10.18087/cardio.2020.11.n1322

31. Fu EL, Desai RJ, Paik JM, Kim DH, Zhang Y, Mastrorilli JM et al. Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: Nationwide US cohort study. Am J Kidney Dis. 2024;83(3):293–305.e1.

PMID: 37839687. PMCID: PMC12032583. https://doi.org/10.1053/j.ajkd.2023.08.017

32. Weir MR, Ashton V, Moore KT, Shrivastava S, Peterson ED, Ammann EM. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV–V chronic kidney disease. Am Heart J. 2020;223:3–11.

PMID: 32112872. https://doi.org/10.1016/j.ahj.2020.01.010

33. Aune D, Feng T, Schlesinger S et al. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32(5):501–11.

PMID: 29653902. https://doi.org/10.1016/j.jdiacomp.2018.02.004

34. Leopoulou M, Theofilis P, Kordalis A et al. Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment. World J Diabetes. 2023;14(5):512–27.

PMID: 37273256. PMCID: PMC10236990. https://doi.org/10.4239/wjd.v14.i5.512

35. Alwafi H, Alotaibi B, Naser AY et al. The safety and efficacy of the use of oral anticoagulant medications in patients with diabetes mellitus: A systematic review. Saudi Pharm J. 2021;29(12):1374–82.

PMID: 35002374. PMCID: PMC8720821. https://doi.org/10.1016/j.jsps.2021.11.001

36. Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR et al.; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170(4):675–682.e8.

PMID: 26386791. https://doi.org/10.1016/j.ahj.2015.07.006

37. Hua Y, Sun JY, Su Y et al. The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: A systematic review and meta-analysis. Am J Cardiovasc Drugs. 2021;21(1):51–61.

PMID: 32514866. https://doi.org/10.1007/s40256-020-00407-z

38. Baker WL, Beyer-Westendorf J, Bunz TJ et al. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. Diab Obes Metab. 2019;21(9):2107–14.

PMID: 31099460. https://doi.org/10.1111/dom.1378

39. Brambatti M, Darius H, Oldgren J et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015;196:127–31.

PMID: 26093161. https://doi.org/10.1016/j.ijcard.2015.05.141

40. Ezekowitz JA, Lewis BS, Lopes RD et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: Results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):86–94.

PMID: 27533976. https://doi.org/10.1093/ehjcvp/pvu024

41. Coleman CI, Costa OS, Brescia CW et al. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Cardiovasc Diabetol. 2021;20(1):52.

PMID: 33637082. PMCID: PMC7913443. https://doi.org/10.1186/s12933-021-01250-5

42. Grymonprez M, Simoens C, Steurbaut S, De Backer TL, Lahousse L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: A systematic review and meta-analysis. Europace. 2022;24(6):887–98.

PMID: 34935033. https://doi.org/10.1093/europace/euab303

43. Arbel A, Abu-Ful Z, Preis M, Cohen S, Saliba W. Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes. J Arrhythmia. 2022;38(1):67–76.

PMID: 35222752. PMCID: PMC8851575. https://doi.org/10.1002/joa3.12656

44. Ozaki AF, Choi AS, Le QT et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969.

PMID: 32148102. https://doi.org/10.1161/CIRCOUTCOMES.119.005969

45. Brízido C, Ferreira AM, Lopes P et al. Medication adherence to direct anticoagulants in patients with non-valvular atrial fibrillation – a real world analysis. Rev Portuguesa Cardiol. 2021;40(9):669–75.

PMID: 34503705. https://doi.org/10.1016/j.repce.2021.07.002

46. Borne RT, O’Donnell C, Turakhia MP et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: Findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):236.

PMID: 28865440. PMCID: PMC5581418. https://doi.org/10.1186/s12872-017-0671-6

47. Jackevicius CA, Tsadok MA, Essebag V et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017;103(17):1331–38.

PMID: 28286333. https://doi.org/10.1136/heartjnl-2016-310672

48. Veale EL. Pharmacy-led management of atrial fibrillation: Improving treatment adherence and patient outcomes. Integr Pharm Res Pract. 2024;13:101–14.

PMID: 39101005. PMCID: PMC11297543. https://doi.org/10.2147/iprp.S397844

49. Rossi AP, Facchinetti R, Ferrari E et al. Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2018;46(2):139–44.

PMID: 29761426. https://doi.org/10.1007/s11239-018-1679-1

50. Quiros Lopez R, Formiga Perez F, Beyer-Westendorf J. Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review. Br J Clin Pharmacol. 2025;91(4):1096–1113.

PMID: 39957057. PMCID: PMC11992665. https://doi.org/10.1002/bcp.70003

51. Abolbashari M. Atherosclerosis and atrial fibrillation: Double trouble. Curr Cardiol Rep. 2022;24(2):67–73.

PMID: 34993746. https://doi.org/10.1007/s11886-021-01625-w

52. Oancea AF, Jigoranu RA, Morariu PC et al. Atrial fibrillation and chronic coronary ischemia: A challenging vicious circle. Life (Basel). 2023;13(6):1370.

PMID: 37374152. PMCID: PMC10305229. https://doi.org/10.3390/life13061370

53. Batta A, Hatwal J, Batta A et al. Atrial fibrillation and coronary artery disease: An integrative review focusing on therapeutic implications of this relationship. World J Cardiol. 2023;15(5):229–43.

PMID: 37274376. PMCID: PMC10237004. https://doi.org/10.4330/wjc.v15.i5.229

54. Miao B, Hernandez AV, Roman YM et al. Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation. Clin Cardiol. 2020;43(5):524–31.

PMID: 32106334. PMCID: PMC7244295. https://doi.org/10.1002/clc.23344

55. Lee CJ, Gerds TA, Carlson N et al. Risk of myocardial infarction in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2018;72(1):17–26.

PMID: 29957227. https://doi.org/10.1016/j.jacc.2018.04.036

56. Chai-Adisaksopha C, Hillis C, Isayama T et al. Mortality outcomes in patients receiving direct oral anticoagulants: A systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2015;13(11):2012–20.

PMID: 26356595. https://doi.org/10.1111/jth.13139

57. Grajek S, Kałuzna-Oleksy M, Siller-Matula JM et al. Non-vitamin K antagonist oral anticoagulants and risk of myocardial infarction in patients with atrial fibrillation with or without percutaneous coronary interventions: A meta-analysis. J Pers Med. 2021;11(10):1013.

PMID: 34683155. PMCID: PMC8539187. https://doi.org/10.3390/jpm11101013

58. Kupo P, Szakacs Z, Solymar M et al. Direct anticoagulants and risk of myocardial infarction, a multiple treatment network meta-analysis. Angiology. 2020;71(1):27–37.

PMID: 31533437. https://doi.org/10.1177/0003319719874255

59. Mahaffey KW, Stevens SR, White HD et al.; ROCKET AF Investigators. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: Results from the ROCKET AF trial. Eur Heart J. 2014;35(4):233–41.

PMID: 24132190. PMCID: PMC3896862. https://doi.org/10.1093/eurheartj/eht428

60. Chatterjee S, Sharma A, Uchino K et al. Rivaroxaban and risk of myocardial infarction: Insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013;24(8):628–35.

PMID: 24145765. https://doi.org/10.1097/MCA.0000000000000031

61. Camm AJ, Amarenco P, Haas S et al.; XANTUS Investigators. XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37(14):1145–53.

PMID: 26330425. PMCID: PMC4823634. https://doi.org/10.1093/eurheartj/ehv466

62. Marín F, Fernández MS, Barón-Esquivias G et al. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban. J Comp Eff Res. 2023;12(3):e220049.

PMID: 36749006. PMCID: PMC10288946. https://doi.org/10.57264/cer-2022-0049

63. De Luca L. Low-dose rivaroxaban: Can cardiovascular events be reduced? Eur Heart J. 2023;Suppl. 25(Suppl C):C20–C26.

PMID: 37125297. PMCID: PMC10132608. https://doi.org/10.1093/eurheartjsupp/suad034

64. Hasific S, Øvrehus KA, Gerke O et al. Extent of arterial calcification by conventional vitamin K antagonist treatment. PLoS One. 2020;15(10):e0241450.

PMID: 33119722. PMCID: PMC7595268. https://doi.org/10.1371/journal.pone.0241450

65. Sonderskov PS, Lindholt JS, Hallas J et al. Association of aortic valve calcification and vitamin K antagonist treatment. Eur Heart J Cardiovasc Imaging. 2020;21(7):718–24.

PMID: 32361722. https://doi.org/10.1093/ehjci/jeaa065

66. Kosciuszek ND, Kalta D, Singh M, Savinova OV. Vitamin K antagonists and cardiovascular calcification: A systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:938567.

PMID: 36061545. PMCID: PMC9437425. https://doi.org/10.3389/fcvm.2022.938567

67. Posch F, Ay C, Stoger H, Kreutz R, Beyer-Westendorf J. Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost. 2019;3(2):207–16.

PMID: 31011705. PMCID: PMC6462762. https://doi.org/10.1002/rth2.12189

68. Bohm M, Ezekowitz MD, Connolly SJ et al. Changes in renal function in patients with atrial fibrillation: An analysis from the RE-LY trial. J Am Coll Cardiol. 2015;65(23):2481–93.

PMID: 26065986. https://doi.org/10.1016/j.jacc.2015.03.577

69. Yao X, Tangri N, Gersh BJ et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70(21):2621–32.

PMID: 29169468. https://doi.org/10.1016/j.jacc.2017.09.1087

70. Coleman CI, Kreutz R, Sood N et al. Rivaroxaban’s impact on renal decline in patients with nonvalvular atrial fibrillation: A US MarketScan claims database analysis. Clin Appl Thrombo Hemost. 2019;1076029619868535.

PMID: 31392894. PMCID: PMC6829639. https://doi.org/10.1177/1076029619868535

71. Hernandez AV Bradley G, Khan M et al. Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. Eur Heart J Qual Care Clin Outcomes. 2020;6(4):301–7.

PMID: 31432074. https://doi.org/10.1093/ehjqcco/qcz047

72. Gonzalez Perez A, Balabanova Y, Saez ME, Brobert G, García Rodríguez LA. Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United Kingdom. Int J Cardiol. 2022;352:165–71.

PMID: 35122912. https://doi.org/10.1016/j.ijcard.2022.01.063

73. Kreutz R, Deray G, Floege J, Gwechenberger M, Hahn K, Luft AR et al.; XARENO registry. Rivaroxaban vs vitamin K antagonist in patients with atrial fibrillation and advanced chronic kidney disease. JACC Adv. 2024;3(2):100813.

PMID: 38939389. PMCID: PMC11198259. https://doi.org/10.1016/j.jacadv.2023.100813

74. Shahzada TS, Guo CL, Lee APW. Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation. Hong Kong Med J. 2022;28(1):24–32.

PMID: 34737236. https://doi.org/10.12809/hkmj209201

75. Dinh PP, Quang Ho TH, Pham HM, Nguyen HH, Ton MT, Tran GS et al. Evaluating renal benefits of rivaroxaban versus vitamin K antagonists in atrial fibrillation: A systematic review and meta-analysis of real-world evidence. Eur Cardiol. 2024;19:e05.

PMID: 38983579. PMCID: PMC11231818. https://doi.org/10.15420/ecr.2024.07